IP Library Granted Patent US 10,006,054
Granted Patent B1
US 10,006,054 · App. 15/934,750 · Granted Jun 26, 2018

Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA

Inventors: Ari E. Friedland (Boston, MA); Hariharan Jayaram (Cambridge, MA); Barrett Ethan Steinberg (Cambridge, MA)
Assignee: EDITAS MEDICINE, INC.
C12N15/907C12N9/22C12N9/96C12N15/102C12N15/11C12N2310/20C12N2810/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,006,054
App. No.
15/934,750
Granted
Jun 26, 2018
Kind
B1
Abstract

Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.

Claims (29)

1. A transiently active genome editing system, comprising: a guide RNA (gRNA) comprising a targeting domain that is complementary to a eukaryotic nucleic acid sequence; and an engineered RNA-guided nuclease encoded by a nucleic acid comprising the eukaryotic nucleotide sequence and a protospacer adjacent motif (PAM), wherein the PAM is recognized by the RNA-guided nuclease and is within or adjacent to the eukaryotic nucleotide sequence,

wherein the engineered RNA-guided nuclease is a Cas9 protein,

wherein the Cas9 protein comprises an amino acid insertion relative to SEQ ID NO: 2 selected from the group consisting of:

E271_N272insGX 6-10 G,

L371_N372insGX 6-10 G, and

Q737_A738insGX 6-10 G; or

wherein the Cas9 protein comprises an amino acid insertion S12_M13insGX 6-10 G relative to SEQ ID NO: 10,

which results in a polypeptide comprising an amino acid sequence having at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 3-5 and 10 and having an RNA-guided nuclease activity.

2. The transiently active genome editing system of claim 1 , wherein the engineered Cas9 protein and the gRNA form a Cas9/gRNA complex.

3. The transiently active genome editing system of claim 2 , wherein the Cas9/gRNA complex is adapted to cleave the nucleic acid encoding the engineered RNA-guided nuclease.

4. The transiently active genome editing system of claim 1 , wherein the engineered Cas9 protein has at least about 80% nuclease activity of a wild-type Cas9 protein.

5. The transiently active genome editing system of claim 1 , wherein the engineered Cas9 protein is encoded by a nucleic acid comprising an insertion, relative to SEQ ID NO: 6, selected from the group consisting of:

c.813_814insN 24-36 ,

c.1113_1114insN 24-36 , and

c.2211_2212insN 24-36 ; or

comprising an insertion c.36_37insN 24-36 relative to SEQ ID NO: 11.

6. The transiently active genome editing system of claim 5 , wherein the engineered Cas9 protein is encoded by a nucleic acid comprising a sequence having at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 7-9 and 11.

7. The transiently active genome editing system of claim 1 , wherein the engineered Cas9 protein is an engineered S. aureus Cas9.

8. The transiently active genome editing system of claim 1 , wherein the system alters both a cellular endogenous target gene and the RNA-guided nuclease expression.

9. The transiently active genome editing system of claim 1 , wherein the eukaryotic nucleic acid sequence is at least 17 nucleotides in length.

10. The transiently active genome editing system of claim 1 , wherein the targeting domain of the gRNA is 16-24 nucleotides in length.

11. The transiently active genome editing system of claim 1 , wherein the engineered Cas9 protein comprises an amino acid insertion relative to SEQ ID NO: 2, which is E271_N272insGX 6-10 G.

12. The transiently active genome editing system of claim 1 , wherein the engineered Cas9 protein comprises an amino acid insertion relative to SEQ ID NO: 2, which is L371_N372insGX 6-10 G.

13. The transiently active genome editing system of claim 1 , wherein the engineered Cas9 protein comprises an amino acid insertion relative to SEQ ID NO: 2, which is Q737_A738insGX 6-10 G.

14. The transiently active genome editing system of claim 1 , wherein the engineered Cas9 protein comprises an amino acid insertion relative to SEQ ID NO: 10, which is S12_M13insGX 6-10 G.

15. The transiently active genome editing system of claim 1 , wherein the nucleic acid encoding the engineered Cas9 protein comprises an insertion relative to SEQ ID NO: 6, which is c.813_814insN 24-36 .

16. The transiently active genome editing system of claim 1 , wherein the nucleic acid encoding the engineered Cas9 protein comprises an insertion relative to SEQ ID NO: 6, which is c.1113_1114insN 24-36 .

17. The transiently active genome editing system of claim 1 , wherein the nucleic acid encoding the engineered Cas9 protein comprises an insertion relative to SEQ ID NO: 6, which is c.2211_2212insN 24-36 .

18. The transiently active genome editing system of claim 1 , wherein the nucleic acid encoding the engineered Cas9 protein comprises an insertion relative to SEQ ID NO: 11, which is c.36_37insN 24-36 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2020
From: FRIEDLAND, ARI E.; JAYARAM, HARIHARAN; STEINBERG, BARRETT ETHAN
To: EDITAS MEDICINE, INC.
Reel/Frame 051787/0178 →
Continuity (3)
Division 15832567 · Dec 5, 2017
Provisional Application 62503640 · May 9, 2017
Provisional Application 62430154 · Dec 5, 2016
Cited By (1)
US 12,247,201